Pages that link to "Q29616624"
Jump to navigation
Jump to search
The following pages link to Anticancer activities of histone deacetylase inhibitors (Q29616624):
Displaying 50 items.
- Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology (Q21198869) (← links)
- Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase–dependent DC functions and regulates experimental graft-versus-host disease in mice (Q24288997) (← links)
- Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP (Q24302531) (← links)
- Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain (Q24311550) (← links)
- HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism (Q24321756) (← links)
- Histone deacetylase 3 localizes to the mitotic spindle and is required for kinetochore-microtubule attachment (Q24321876) (← links)
- Class IIb HDAC6 regulates endothelial cell migration and angiogenesis by deacetylation of cortactin (Q24322940) (← links)
- Lys-63-specific deubiquitination of SDS3 by USP17 regulates HDAC activity (Q24337169) (← links)
- Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes (Q24338109) (← links)
- Epigenetics of colorectal cancer (Q24598045) (← links)
- Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy (Q24603793) (← links)
- The many roles of histone deacetylases in development and physiology: implications for disease and therapy (Q24628821) (← links)
- Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia (Q24633394) (← links)
- Histone deacetylase inhibitors: Potential in cancer therapy (Q24649025) (← links)
- Global sequencing of proteolytic cleavage sites in apoptosis by specific labeling of protein N termini (Q24653446) (← links)
- HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination (Q24670026) (← links)
- Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment (Q26740619) (← links)
- Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies (Q26744080) (← links)
- Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future (Q26746934) (← links)
- Targeted drugs in small-cell lung cancer (Q26767017) (← links)
- Potential use of histone deacetylase inhibitors in cancer therapy (Q26769594) (← links)
- Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role (Q26769734) (← links)
- Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade (Q26769977) (← links)
- Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand? (Q26771601) (← links)
- Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer (Q26777453) (← links)
- Relationship between intestinal microbiota and colorectal cancer (Q26781449) (← links)
- Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy (Q26783032) (← links)
- Histone Deacetylases and Their Regulatory MicroRNAs in Hepatocarcinogenesis (Q26783620) (← links)
- Romidepsin for the Treatment of Peripheral T-Cell Lymphoma (Q26785732) (← links)
- Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review (Q26796449) (← links)
- Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer? (Q26798882) (← links)
- New molecular targets in mantle cell lymphoma (Q26821766) (← links)
- Small molecule inhibitors of zinc-dependent histone deacetylases (Q26824515) (← links)
- Epigenetic dysregulation in Epstein-Barr virus-associated gastric carcinoma: disease and treatments (Q26828724) (← links)
- EGFR Amplification and Glioblastoma Stem-Like Cells (Q26853549) (← links)
- Keep-ING balance: tumor suppression by epigenetic regulation (Q26859017) (← links)
- Metabolic reprogramming by class I and II histone deacetylases (Q26860745) (← links)
- Applicability of histone deacetylase inhibition for the treatment of spinal muscular atrophy (Q26864605) (← links)
- Histone deacetylases as targets for treatment of multiple diseases (Q27000389) (← links)
- Trials with 'epigenetic' drugs: an update (Q27000542) (← links)
- Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells (Q27015931) (← links)
- Lysine deacetylase (KDAC) regulatory pathways: an alternative approach to selective modulation (Q27021965) (← links)
- New and emerging HDAC inhibitors for cancer treatment (Q27022413) (← links)
- Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson's disease (Q27301885) (← links)
- Therapeutic efficacy of valproic acid in a combined monocrotaline and chronic hypoxia rat model of severe pulmonary hypertension (Q27316522) (← links)
- HDACi Valproic Acid (VPA) and Suberoylanilide Hydroxamic Acid (SAHA) Delay but Fail to Protect against Warm Hepatic Ischemia-Reperfusion Injury (Q27327201) (← links)
- Structural basis of histone demethylation by LSD1 revealed by suicide inactivation (Q27644954) (← links)
- Human HDAC7 Harbors a Class IIa Histone Deacetylase-specific Zinc Binding Motif and Cryptic Deacetylase Activity (Q27649881) (← links)
- Structural Basis of the Antiproliferative Activity of Largazole, a Depsipeptide Inhibitor of the Histone Deacetylases (Q27671010) (← links)
- Atomic resolution structure of human -tubulin acetyltransferase bound to acetyl-CoA (Q27674573) (← links)